Figure 7.

Average ⁶⁸Ga-DOTATOC SUVmean of A549 and Panc-1 tumors in different groups. (A) The SUVmean of the A549_TD tumors which did not receive PRRT remained high and statistically unchanged compared to baseline after 18 days. The SUVmean of the treated A549_TD decreased at every time point until day 18 post treatment and became significantly lower than that of non-treated A549_TD xenografts at day 14 (1.6 ± 0.2 vs. 2.8 ± 0.4, respectively; p = 0.023) and 18 (1.2 ± 0.1 vs. 3.0 ± 0.6, respectively; p = 0.017) imaging time points, but remained consistently higher than that of A549_WT xenografts at all imaging time points. As expected, the SUVmean of the 50% TD and 10% TD tumors were between those of 100% A549_TD and A549_WT at baseline and significantly decreased by day 18 compared to baseline (p < 0.03 and p = 0.047, respectively). (B) The SUVmean of the non-treated Panc-1_TD tumors remained high and statistically unchanged compared to baseline after 18 days. The SUVmean of the treated Panc-1_TD tumors was significantly lower than that of the non-treated group by day 5 after ⁹⁰Y-DOTATOC treatment (0.7 ± 0.1 vs. 1.3 ± 0.1, respectively; p = 0.007) and further decreased over time to comparable levels compared to Panc-1_WT xenografts by day 18. The SUVmean of the 50% TD and 10% TD tumors were between those of 100% Panc-1_TD and Panc-1_WT at baseline and significantly decreased by day 18 compared to baseline (p < 0.0001 and p = 0.0042, respectively).